NICE approves Amgen’s leukaemia treatment

NICE announces the recommendation of Amgen’s blinatumomab for treating acute lymphoblastic leukaemia (ALL). The indication is for patients in first complete remission with minimal residual disease (MRD) activity of at least 0.1%. This decision to recommend the drug as a cost-effective use of NHS resources was made after the submission of new evidence from the

Continue Reading

Akcea obtains NICE approval for stage 1 or 2 polyneuropathy in adult patients with hATTR

Akcea Therapeutics’ Inotersen has received recommendation from NICE, meaning the therapy will now be made available to NHS patients in England and Wales for the treatment of Stage 1 or Stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR).  hATTR is a serious condition caused by “the abnormal formation of the TTR protein

Continue Reading

NICE partners with EMIG

NICE and EMIG are working together to increase understanding of the services the Institute offers the life sciences industry. The collaboration also aims to open up a new channel for the industry to give feedback to NICE to inform any review, monitoring or refinement of its processes. The partnership will run as a pilot scheme

Continue Reading

NICE approves UCB’s treatment for Psoriasis but disapproved Almirall’s

The public body has recommended in draft guidance that UCB’s Certolizumab pegol receives regular NHS funding for plaque psoriasis, although NICE decided that Almirall’s rival Tildrakizumab is not cost effective. Certolizumab pegol has been previously approved in Europe in the new indication of plaque psoriasis, thereby adding to a list of uses including rheumatoid arthritis,

Continue Reading

NHS approves combination skin cancer therapy from Novartis

NHS has three months to ensure that Novartis’ combination therapy dabrafenib/trametinib is routinely available to eligible skin cancer patients, after cost regulators published guidance backing funds for the treatment. NICE recommended the combination for use in patients with stage III BRAF V600 mutation-positive melanoma that has spread to lymph vessels, or lymph glands close to

Continue Reading

Nice set to collaborate with Greater Manchester to improve health of locals

A partnership between Greater Manchester and NICE that was created with the aim of improving the health of the local population has been extended for another three years. A Memorandum of Understanding has been agreed between NICE, Health Innovation Manchester and The University of Manchester outlining a shared commitment to boosting health through research, informing

Continue Reading

Janssen’s Zytiga has been rejected by NICE for early treatment of aggressive prostate cancer

Experts state that it is looking highly unlikely that Janssen’s Zytiga plus androgen deprivation therapy (ADT) and prednisone/prednisolone will become routinely available on the NHS as a first-line treatment for patients with high-risk hormone-sensitive metastatic prostate cancer.   NICE have published draft guidelines rejecting the therapy in this setting, after concluding that the company’s economic

Continue Reading